nach oben

Erschienen in:

04.05.2016 | Review Article

Safety and efficacy of primary thromboprophylaxis in cancer patients

verfasst von: I. García Escobar, M. Antonio Rebollo, S. García Adrián, A. Rodríguez-Garzotto, A. Muñoz Martín, Cancer&Thrombosis Working Group of the Spanish Society of Medical Oncology (SEOM)

Erschienen in: Clinical and Translational Oncology | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Cancer is often complicated by venous thromboembolism (VTE), a common and potentially fatal complication associated with poor prognosis in these patients. An increased incidence of VTE is being observed due to the advanced age of cancer patients, the thrombogenic effect of novel drugs and advances in the diagnosis of related complications. In this review, we look at five different risk groups of cancer patients with an increased probability of developing VTE, including hospitalized patients undergoing chemotherapy, patients undergoing a surgical procedure, ambulatory patients undergoing chemotherapy, patients with a central venous access and patients receiving antiangiogenic drugs or anticoagulant therapy due to previous chronic diseases. The aim of this review is to summarize the most important clinical evidence reported to date on the suitability of primary thromboprophylaxis to cancer patients. Recommendations have drawn up for each group based on current evidence and guidelines to facilitate decision-making in clinical practice.

Franchini M, Montagnana M, Targher G, Manzato F, Lippi G. Pathogenesis, clinical and laboratory aspects of thrombosis in cancer. J Thromb Thrombolysis. 2007;24(1):29–38. doi:10.1007/s11239-007-0028-6.PubMedCrossRef

Epstein AS, Soff GA, Capanu M, Crosbie C, Shah MA, Kelsen DP, et al. Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer. Cancer. 2012;118(12):3053–61. doi:10.1002/cncr.26600.PubMedCrossRef

Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(Suppl 6):381S–453S. doi:10.1378/chest.08-0656.PubMedCrossRef

Dennis M, Sandercock PA, Reid J, Graham C, Murray G, Venables G, et al. Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial. Lancet. 2009;373(9679):1958–65. doi:10.1016/S0140-6736(09)60941-7.PubMedCrossRef

Bozzato S, Galli L, Ageno W. Thromboprophylaxis in surgical and medical patients. Semin Respir Crit Care Med. 2012;33(2):163–75. doi:10.1055/s-0032-1311795.PubMedCrossRef

Leizorovicz A, Mismetti P. Preventing venous thromboembolism in medical patients. Circulation. 2004;110(Suppl 4):IV13–9. doi:10.1161/01.CIR.0000150640.98772.af.PubMed

Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 2006;332(7537):325–9. doi:10.1136/bmj.38733.466748.7C.PubMedPubMedCentralCrossRef

Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A, et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis. 2003;14(4):341–6.PubMedCrossRef

Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F, et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol. 2011;29(8):986–93. doi:10.1200/JCO.2010.31.6844.PubMedCrossRef

10.

Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2013;31(17):2189–204. doi:10.1200/JCO.2013.49.1118.PubMedCrossRef

11.

Kuderer NM, Lyman GH. Guidelines for treatment and prevention of venous thromboembolism among patients with cancer. Thromb Res. 2014;133(Suppl 2):S122–7. doi:10.1016/S0049-3848(14)50021-7.PubMedPubMedCentralCrossRef

12.

Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ, American College of Chest Physicians Antithrombotic T, et al. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(Suppl 2):7S–47S. doi:10.1378/chest.1412S3.PubMedPubMedCentralCrossRef

13.

Mandala M, Falanga A, Roila F, Group EGW. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2011;22(Suppl 6):vi85–92. doi:10.1093/annonc/mdr392.PubMed

14.

NCCN Clinical Practice Guidelines in Oncology. Cancer-associated venous thromboembolic disease. Version 1.2015. http://www.nccn.org/professionals/physician_gls/pdf/vte.pdf. Accessed Aug 2015.

15.

Farge D, Debourdeau P, Beckers M, Baglin C, Bauersachs RM, Brenner B, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost. 2013;11(1):56–70. doi:10.1111/jth.12070.PubMedCrossRef

16.

Muñoz AJ, Viñolas N, Cubedo R, Isla D. SEOM guidelines on thrombosis in cancer patients. Clin Transl Oncol. 2011;13(8):592–6. doi:10.1007/s12094-011-0703-0.PubMedCrossRef

17.

Cohen AT, Tapson VF, Bergmann JF, Goldhaber SZ, Kakkar AK, Deslandes B, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008;371(9610):387–94. doi:10.1016/S0140-6736(08)60202-0.PubMedCrossRef

18.

Zurawska U, Parasuraman S, Goldhaber SZ. Prevention of pulmonary embolism in general surgery patients. Circulation. 2007;115(9):e302–7. doi:10.1161/CIRCULATIONAHA.106.674663.PubMedCrossRef

19.

Agnelli G, Bolis G, Capussotti L, Scarpa RM, Tonelli F, Bonizzoni E, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg. 2006;243(1):89–95.PubMedPubMedCentralCrossRef

20.

Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA Jr, et al. Prevention of venous thromboembolism. Chest. 2001;119(Suppl 1):132S–75S.PubMedCrossRef

21.

Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002;346(13):975–80. doi:10.1056/NEJMoa012385.PubMedCrossRef

22.

Rasmussen MS, Jorgensen LN, Wille-Jorgensen P. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. Cochrane Database Syst Rev. 2009;1:CD004318. doi:10.1002/14651858.CD004318.pub2.

23.

Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902–7. doi:10.1182/blood-2007-10-116327.PubMedPubMedCentralCrossRef

24.

Ay C, Dunkler D, Marosi C, Chiriac AL, Vormittag R, Simanek R, et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116(24):5377–82. doi:10.1182/blood-2010-02-270116.PubMedCrossRef

25.

Haas SK, Freund M, Heigener D, Heilmann L, Kemkes-Matthes B, von Tempelhoff GF, et al. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer. Clin Appl Thromb Hemost. 2012;18(2):159–65. doi:10.1177/1076029611433769.PubMedCrossRef

26.

Agnelli G, Gussoni G, Bianchini C, Verso M, Mandala M, Cavanna L, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009;10(10):943–9. doi:10.1016/S1470-2045(09)70232-3.PubMedCrossRef

27.

Barni S, Petrelli F, Bonizzoni E, Verso M, Gussoni G, Perrone T, et al. Survival benefit with low-molecular-weight heparin in patients with advanced solid tumors: a post hoc analysis of PROTECHT trial. J Clin Oncol. 2014;32(Suppl 5):Abstract 9640.

28.

Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med. 2012;7(3):291–2. doi:10.1007/s11739-012-0784-y.PubMedCrossRef

29.

Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012;366(7):601–9. doi:10.1056/NEJMoa1108898.PubMedCrossRef

30.

Agnelli G, Fisher W, Kakkar AK, Lassen MR, Mismetti P, Mouret P, et al. Venous thromboembolism (VTE) prevention with semuloparin in cancer patients initiating chemotherapy: benefit-risk assessment by VTE Risk in SAVE-ONCO. 53rd ASH Annual Meeting and Exposition. 2011:Abstract 206.

31.

Maraveyas A, Waters J, Roy R, Fyfe D, Propper D, Lofts F, et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer. 2012;48(9):1283–92. doi:10.1016/j.ejca.2011.10.017.PubMedCrossRef

32.

Pelzer U, Opitz B, Deutschinoff G, Stauch M, Reitzig PC, Hahnfeld S, et al. Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 Trial. J Clin Oncol. 2015;33(18):2028–34. doi:10.1200/JCO.2014.55.1481.PubMedCrossRef

33.

Perry JR, Julian JA, Laperriere NJ, Geerts W, Agnelli G, Rogers LR, et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost. 2010;8(9):1959–65. doi:10.1111/j.1538-7836.2010.03973.x.PubMedCrossRef

34.

Di Nisio M, Porreca E, Ferrante N, Otten HM, Cuccurullo F, Rutjes AW. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev. 2012;2:CD008500. doi:10.1002/14651858.CD008500.pub2.

35.

Akl EA, Schunemann HJ. Routine heparin for patients with cancer? One answer, more questions. N Engl J Med. 2012;366(7):661–2. doi:10.1056/NEJMe1113672.PubMedCrossRef

36.

Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014. J Clin Oncol. 2015;33(6):654–6. doi:10.1200/JCO.2014.59.7351.PubMedPubMedCentralCrossRef

37.

Streiff MB, Bockenstedt PL, Cataland SR, Chesney C, Eby C, Fanikos J, et al. Venous thromboembolic disease. J Natl Compr Canc Netw. 2013;11(11):1402–29.PubMed

38.

Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(Suppl 2):e419S–94S. doi:10.1378/chest.11-2301.PubMedPubMedCentralCrossRef

39.

Khorana AA, Otten HM, Zwicker JI, Connolly GC, Bancel DF, Pabinger I, et al. Prevention of venous thromboembolism in cancer outpatients: guidance from the SSC of the ISTH. J Thromb Haemost. 2014;12(11):1928–31. doi:10.1111/jth.12725.PubMedCrossRef

40.

Akl EA, Vasireddi SR, Gunukula S, Yosuico VE, Barba M, Sperati F, et al. Anticoagulation for patients with cancer and central venous catheters. Cochrane Database Syst Rev. 2011;4:CD006468. doi:10.1002/14651858.CD006468.pub4.

41.

Kuter DJ. Thrombotic complications of central venous catheters in cancer patients. Oncologist. 2004;9(2):207–16.PubMedCrossRef

42.

Lee AY, Levine MN, Butler G, Webb C, Costantini L, Gu C, et al. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol. 2006;24(9):1404–8. doi:10.1200/JCO.2005.03.5600.PubMedCrossRef

43.

Verso M, Agnelli G, Bertoglio S, Di Somma FC, Paoletti F, Ageno W, et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol. 2005;23(18):4057–62. doi:10.1200/JCO.2005.06.084.PubMedCrossRef

44.

Couban S, Goodyear M, Burnell M, Dolan S, Wasi P, Barnes D, et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol. 2005;23(18):4063–9. doi:10.1200/JCO.2005.10.192.PubMedCrossRef

45.

Young AM, Billingham LJ, Begum G, Kerr DJ, Hughes AI, Rea DW, et al. Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet. 2009;373(9663):567–74. doi:10.1016/S0140-6736(09)60205-1.PubMedCrossRef

46.

De Cicco M, Matovic M, Balestreri L, Steffan A, Pacenzia R, Malafronte M, et al. Early and short-term acenocumarine or dalteparin for the prevention of central vein catheter-related thrombosis in cancer patients: a randomized controlled study based on serial venographies. Ann Oncol. 2009;20(12):1936–42. doi:10.1093/annonc/mdp235.PubMedCrossRef

47.

Abdelkefi A, Ben Othman T, Kammoun L, Chelli M, Romdhane NB, Kriaa A, et al. Prevention of central venous line-related thrombosis by continuous infusion of low-dose unfractionated heparin, in patients with haemato-oncological disease. A randomized controlled trial. Thromb Haemost. 2004;92(3):654–61. doi:10.1267/THRO04090000.PubMed

48.

Karthaus M, Kretzschmar A, Kroning H, Biakhov M, Irwin D, Marschner N, et al. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol. 2006;17(2):289–96. doi:10.1093/annonc/mdj059.PubMedCrossRef

49.

Mismetti P, Mille D, Laporte S, Charlet V, Buchmuller-Cordier A, Jacquin JP, et al. Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial. Haematologica. 2003;88(1):67–73.PubMed

50.

Akl EA, Kahale L, Barba M, Neumann I, Labedi N, Terrenato I, et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev. 2014;7:CD006650. doi:10.1002/14651858.CD006650.pub4.

51.

Lavau-Denes S, Lacroix P, Maubon A, Preux PM, Genet D, Venat-Bouvet L, et al. Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study. Cancer Chemother Pharmacol. 2013;72(1):65–73. doi:10.1007/s00280-013-2169-y.PubMedCrossRef

52.

Dillon PW, Jones GR, Bagnall-Reeb HA, Buckley JD, Wiener ES, Haase GM, et al. Prophylactic urokinase in the management of long-term venous access devices in children: a Children’s Oncology Group study. J Clin Oncol. 2004;22(13):2718–23. doi:10.1200/JCO.2004.07.019.PubMedCrossRef

53.

Ray CE Jr, Shenoy SS, McCarthy PL, Broderick KA, Kaufman JA. Weekly prophylactic urokinase instillation in tunneled central venous access devices. J Vasc Interv Radiol. 1999;10(10):1330–4.PubMedCrossRef

54.

Solomon B, Moore J, Arthur C, Prince HM. Lack of efficacy of twice-weekly urokinase in the prevention of complications associated with Hickman catheters: a multicentre randomised comparison of urokinase versus heparin. Eur J Cancer. 2001;37(18):2379–84.PubMedCrossRef

55.

Saber W, Moua T, Williams EC, Verso M, Agnelli G, Couban S, et al. Risk factors for catheter-related thrombosis (CRT) in cancer patients: a patient-level data (IPD) meta-analysis of clinical trials and prospective studies. J Thromb Haemost. 2011;9(2):312–9. doi:10.1111/j.1538-7836.2010.04126.x.PubMedPubMedCentralCrossRef

56.

Debourdeau P, Farge D, Beckers M, Baglin C, Bauersachs RM, Brenner B, et al. International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J Thromb Haemost. 2013;11(1):71–80. doi:10.1111/jth.12071.PubMedCrossRef

57.

Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99(16):1232–9. doi:10.1093/jnci/djm086.PubMedCrossRef

58.

Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008;300(19):2277–85. doi:10.1001/jama.2008.656.PubMedCrossRef

59.

Hurwitz HI, Saltz LB, Van Cutsem E, Cassidy J, Wiedemann J, Sirzen F, et al. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol. 2011;29(13):1757–64. doi:10.1200/JCO.2010.32.3220.PubMedCrossRef

60.

Catovsky D, Ikoku NB, Pitney WR, Galton DA. Thromboembolic complications in myelomatosis. Br Med J. 1970;3(5720):438–9.PubMedPubMedCentralCrossRef

61.

Baz R, Li L, Kottke-Marchant K, Srkalovic G, McGowan B, Yiannaki E, et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc. 2005;80(12):1568–74. doi:10.4065/80.12.1568.PubMedCrossRef

62.

Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357(21):2123–32. doi:10.1056/NEJMoa070594.PubMedCrossRef

63.

Osman K, Comenzo R, Rajkumar SV. Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med. 2001;344(25):1951–2. doi:10.1056/NEJM200106213442516.PubMedCrossRef

64.

Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006;354(10):1021–30. doi:10.1056/NEJMoa053583.PubMedCrossRef

65.

Cavo M, Zamagni E, Tosi P, Cellini C, Cangini D, Tacchetti P, et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica. 2004;89(7):826–31.PubMed

66.

Hulin C, Facon T, Rodon P, Pegourie B, Benboubker L, Doyen C, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol. 2009;27(22):3664–70. doi:10.1200/JCO.2008.21.0948.PubMedCrossRef

67.

Zervas K, Dimopoulos MA, Hatzicharissi E, Anagnostopoulos A, Papaioannou M, Mitsouli C, et al. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. Ann Oncol. 2004;15(1):134–8.PubMedCrossRef

68.

Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Eastern Cooperative Oncology G. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24(3):431–6. doi:10.1200/JCO.2005.03.0221.PubMedCrossRef

69.

Mateos MV, Oriol A, Martinez-Lopez J, Gutierrez N, Teruel AI, Lopez de la Guia A, et al. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood. 2012;120(13):2581–8. doi:10.1182/blood-2012-05-427815.PubMedCrossRef

70.

Harousseau JL, Attal M, Leleu X, Troncy J, Pegourie B, Stoppa AM, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica. 2006;91(11):1498–505.PubMed

71.

Zonder JA, Barlogie B, Durie BG, McCoy J, Crowley J, Hussein MA. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood. 2006;108(1):403; author reply 4. doi:10.1182/blood-2006-01-0154.

72.

Gay F, Hayman SR, Lacy MQ, Buadi F, Gertz MA, Kumar S, et al. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood. 2010;115(7):1343–50. doi:10.1182/blood-2009-08-239046.PubMedPubMedCentralCrossRef

73.

Eby C. Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias. Br J Haematol. 2009;145(2):151–63. doi:10.1111/j.1365-2141.2008.07577.x.PubMedCrossRef

74.

Knight R, DeLap RJ, Zeldis JB. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med. 2006;354(19):2079–80. doi:10.1056/NEJMc053530.PubMedCrossRef

75.

Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11(1):29–37. doi:10.1016/S1470-2045(09)70284-0.PubMedCrossRef

76.

Palumbo A, Cavo M, Bringhen S, Cavalli M, Patriarca F, Rossi R, et al. A phase III study of enoxaparin vs aspirin vs low-dose warfarin as thromboprophylaxis for newly diagnosed myeloma patients treated with thalidomide based-regimens. Blood (ASH Annual Meeting Abstracts). 2009;114(22):Abstract 492.

77.

Palumbo A, Cavallo F, Yehuda DB, Omedè P, Siniscalchi A, Cavalli M, et al. A prospective, randomized study of melphalan, prednisone, lenalidomide (MPR) versus melphalan (200 Mg/M2) and autologous transplantation (Mel200) in newly diagnosed myeloma patients: an interim analysis. Blood (ASH Annual Meeting Abstracts). 2009;114(22):Abstract 350.

78.

Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A, et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood. 2012;119(4):933–9. doi:10.1182/blood-2011-03-344333 quiz 1093.PubMedCrossRef

79.

Bennett CL, Angelotta C, Yarnold PR, Evens AM, Zonder JA, Raisch DW, et al. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA. 2006;296(21):2558–60. doi:10.1001/jama.296.21.2558-c.PubMedCrossRef

80.

El Accaoui RN, Shamseddeen WA, Taher AT. Thalidomide and thrombosis. A meta-analysis. Thromb Haemost. 2007;97(6):1031–6.PubMed

81.

Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22(2):414–23. doi:10.1038/sj.leu.2405062.PubMedCrossRef

82.

Rana P, Levine MN. Prevention of thrombosis in ambulatory patients with cancer. J Clin Oncol. 2009;27(29):4885–8. doi:10.1200/JCO.2009.23.5481.PubMedCrossRef

83.

Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863–9. doi:10.1200/JCO.2015.61.2267.PubMedPubMedCentralCrossRef

84.

Zacharski LR, Prandoni P, Monreal M. Warfarin versus low-molecular-weight heparin therapy in cancer patients. Oncologist. 2005;10(1):72–9. doi:10.1634/theoncologist.10-1-72.PubMedCrossRef

85.

Noble SI, Shelley MD, Coles B, Williams SM, Wilcock A, Johnson MJ, et al. Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis. Lancet Oncol. 2008;9(6):577–84. doi:10.1016/S1470-2045(08)70149-9.PubMedCrossRef

86.

Grogan KM, Wong C, Nutescu EA, Shord SS. Examining differences in weekly warfarin dose in patients with and without cancer. Ther Drug Monit. 2007;29(5):638–43. doi:10.1097/FTD.0b013e318074dc46.PubMedCrossRef

87.

Le Maitre A, Ding K, Shepherd FA, Leighl N, Arnold A, Seymour L, et al. Anticoagulation and bleeding: a pooled analysis of lung cancer trials of the NCIC Clinical Trials Group. J Thorac Oncol. 2009;4(5):586–94. doi:10.1097/JTO.0b013e31819f9a8a.PubMedCrossRef

88.

Arai S, Mitsufuji H, Nishii Y, Onoda S, Ryuge S, Wada M, et al. Effect of gefitinib on warfarin antithrombotic activity. Int J Clin Oncol. 2009;14(4):332–6. doi:10.1007/s10147-008-0871-2.PubMedCrossRef

89.

Saif MW, Wasif N. Interaction between capecitabine and gemcitabine with warfarin in a patient with pancreatic cancer. JOP. 2008;9(6):739–43.PubMed

90.

Yano R, Kurokawa T, Tsuyoshi H, Shinagawa A, Sawamura Y, Matsunaga A, et al. Transient elevation of international normalized ratio during cisplatin-based chemotherapy in patients who are taking warfarin. Ann Pharmacother. 2011;45(10):e55. doi:10.1345/aph.1Q290.PubMedCrossRef

Titel: Safety and efficacy of primary thromboprophylaxis in cancer patients
verfasst von: I. García Escobar
M. Antonio Rebollo
S. García Adrián
A. Rodríguez-Garzotto
A. Muñoz Martín
Cancer&Thrombosis Working Group of the Spanish Society of Medical Oncology (SEOM)
Publikationsdatum: 04.05.2016
Verlag: Springer International Publishing
Erschienen in: Clinical and Translational Oncology / Ausgabe 1/2017
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-016-1500-6

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Safety and efficacy of primary thromboprophylaxis in cancer patients

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

Spanish consensus for the management of patients with anaplastic cell thyroid carcinoma

Downregulated ECRG4 is correlated with lymph node metastasis and predicts poor outcome for nasopharyngeal carcinoma patients

Metastatic neuroblastoma in infants: are survival rates excellent only within the stringent framework of clinical trials?

Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study

CT scan prior to radiotherapy in unresectable, locally advanced, non-small cell carcinoma of the lung: is it always necessary?

Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie